Publications by authors named "Lyndsay N Harris"

70Publications

Reduction of Global H3K27me Enhances HER2/ErbB2 Targeted Therapy.

Cell Rep 2019 10;29(2):249-257.e8

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.08.105DOI Listing
October 2019

Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.

JNCI Cancer Spectr 2017 Sep 11;1(1):pkx008. Epub 2017 Dec 11.

National Cancer Institute, National Institutes of Health, Bethesda, MD (ATN); Patient Advocates in Research (PAIR), Danville, CA (DEC); National Cancer Institute, Cancer Diagnosis Program, National Institutes of Health, Rockville, MD (LNH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pkx008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649766PMC
September 2017

Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al.

J Clin Oncol 2016 11;34(32):3946-3948

Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.7020DOI Listing
November 2016

"An addendum to breast cancer": the triple negative experience.

Support Care Cancer 2016 09 1;24(9):3715-21. Epub 2016 Apr 1.

Yale School of Nursing in West Haven, West Haven, CT, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-016-3184-4
Publisher Site
http://dx.doi.org/10.1007/s00520-016-3184-4DOI Listing
September 2016

Biomarkers for Predicting Response to Anti-HER2 Agents.

Adv Exp Med Biol 2016 ;882:155-67

Seidman Cancer Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22909-6_6DOI Listing
August 2016

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer Cell 2016 Mar;29(3):255-269

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794996PMC
March 2016

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

J Oncol Pract 2016 Apr 8;12(4):384-9. Epub 2016 Mar 8.

Case Western Reserve University, Cleveland, OH; American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.010868DOI Listing
April 2016

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2016 Apr 8;34(10):1134-50. Epub 2016 Feb 8.

Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/02/05/JCO.2015.65
Web Search
http://www.instituteforquality.org/sites/instituteforquality
Web Search
http://www.instituteforquality.org/sites/instituteforquality
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.65.2289
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933134PMC
April 2016

Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma.

Arch Pathol Lab Med 2015 Dec;139(12):1546-9

From the Departments of Pathology (Drs Bomeisl and Gilmore), Family Medicine and Community Health (Dr Thompson), and Hematology and Oncology (Dr Harris), University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2014-0557-OADOI Listing
December 2015

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Oncol Pract 2015 Nov;11(6):514-516

Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.005215DOI Listing
November 2015

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2015 Aug 20;33(24):2695-704. Epub 2015 Jul 20.

Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Robert C. Bast, Ana M. Gonzalez-Angulo, and William F. Symmans, University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Texas Oncology, Dallas, TX; Massimo Cristofanilli, Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA; Matthew P. Goetz and Minetta C. Liu, Mayo Clinic, Rochester, MN; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Elizabeth G. Hill, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC; Wanda Lucas, Georgetown University, Washington, DC; Ingrid A. Mayer, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; and Lyndsay N. Harris, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.1459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102PMC
August 2015

Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer.

Breast Cancer Res Treat 2015 Apr 8;150(2):321-34. Epub 2015 Mar 8.

Departments of Genetics and Genome Sciences, Case Western Reserve University, Case Western Reserve University, Cleveland, OH, 44106, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-015-3327-1
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3327-1DOI Listing
April 2015

The renaissance of endocrine therapy in breast cancer.

Curr Opin Obstet Gynecol 2014 Feb;26(1):41-7

aSeidman Cancer Center, University Hospitals of Case Western Cleveland bDivision of Hematology/Oncology, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0000000000000039DOI Listing
February 2014

Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

PLoS One 2013 18;8(11):e71915. Epub 2013 Nov 18.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America ; Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071915PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832509PMC
July 2014

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Clin Cancer Res 2013 Oct 21;19(20):5798-807. Epub 2013 Aug 21.

Authors' Affiliations: Section of Biostatistics; Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology; Division of Biomedical Statistics and Informatics and Medical Oncology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology and Hematology/Oncology, Mayo Clinic, Jacksonville, Florida; Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania; The Angeles Clinic and Research Institute, Santa Monica, California; Indiana University Medical Center Cancer Pavilion, Indianapolis, Indiana; Division of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa; Seattle Cancer Care Alliance, Seattle, Washington; and Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805021PMC
October 2013

DTCs/CTCs in breast cancer: five decades later.

Recent Results Cancer Res 2012 ;195:217-25

Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-28160-0_20DOI Listing
July 2012

Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.

Cancer 2012 Oct 22;118(19):4660-9. Epub 2012 Feb 22.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391341PMC
October 2012

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Breast Cancer Res 2011 Nov 2;13(5):R85. Epub 2011 Nov 2.

Yale University School of Medicine, Department of Pathology, 310 Cedar St, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262195PMC
November 2011

Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma.

Breast Cancer Res 2011 May 18;13(3):R51. Epub 2011 May 18.

Division of Biostatistics, Yale University School of Public Health, New Haven, CT 06511, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2882DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218938PMC
May 2011

Molecular predictors of response to therapy for breast cancer.

Cancer J 2011 Mar-Apr;17(2):96-103

Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318212dee3DOI Listing
July 2011

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.

Breast Cancer Res 2010 9;12(4):R62. Epub 2010 Aug 9.

Department of Internal Medicine (Section of Medical Oncology), Yale Cancer Center and Smilow Cancer Hospital at Yale-New-Haven Hospital, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949655PMC
March 2011

Global variation in CYP2C8-CYP2C9 functional haplotypes.

Pharmacogenomics J 2009 Aug 21;9(4):283-90. Epub 2009 Apr 21.

Department of Genetics, Yale University School of Medicine, New Haven, CT 06520-8005, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/tpj.2009.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782405PMC
August 2009

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Cancer Res 2009 Mar 10;69(6):2191-4. Epub 2009 Mar 10.

Division of Medical Oncology, Yale Cancer Center, Yale University, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-1056DOI Listing
March 2009

Genomic analysis from tissue core biopsies: standard of care for the future?

Breast Cancer Res Treat 2009 Dec 21;118(3):645-6. Epub 2009 Feb 21.

Yale Comprehensive Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0337-xDOI Listing
December 2009

Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer.

Cancer 2008 Nov;113(9):2565-74

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8040, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23881DOI Listing
November 2008

Triple negative breast cancer: current understanding of biology and treatment options.

Curr Opin Obstet Gynecol 2008 Feb;20(1):40-6

Section of Medical Oncology, Yale University School of Medicine/Yale Cancer Center, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0b013e3282f40de9DOI Listing
February 2008

Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery.

J Proteome Res 2006 Nov;5(11):2947-55

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/pr060099u
Publisher Site
http://dx.doi.org/10.1021/pr060099uDOI Listing
November 2006

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Nat Genet 2006 Sep 20;38(9):1043-8. Epub 2006 Aug 20.

Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology (CHIP@HST), Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ng1861
Publisher Site
http://dx.doi.org/10.1038/ng1861DOI Listing
September 2006

Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.

BMC Bioinformatics 2006 Apr 10;7:197. Epub 2006 Apr 10.

Bioinformatics Div, TNLIST, Dept of Automation, Tsinghua University, Beijing, 100084, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2105-7-197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1456993PMC
April 2006

Requirement for CDK4 kinase function in breast cancer.

Cancer Cell 2006 Jan;9(1):23-32

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2005.12.012DOI Listing
January 2006

A role for the scaffolding adapter GAB2 in breast cancer.

Nat Med 2006 Jan 20;12(1):114-21. Epub 2005 Dec 20.

Cancer Biology Program, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, NRB 1030, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nm1341
Publisher Site
http://dx.doi.org/10.1038/nm1341DOI Listing
January 2006

The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.

Clin Breast Cancer 2002 Jun;3(2):125-35; discussion 136-7

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cbc.2002.n.017DOI Listing
June 2002

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

J Clin Oncol 2002 Feb;20(3):719-26

University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.3.719DOI Listing
February 2002